Voulez-vous consulter la version mobile de ce site ?

Biography

Yibin Kang

Yibin Kang

Yibin Kang is a Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University. A graduate of Fudan University, Dr. Kang completed his graduate study at Duke and postdoctoral training at the Memorial Sloan-Kettering Cancer Center. He joined the faculty of Princeton University in 2004 and was promoted to Associate Professor in 2010 and to Endowed Chair Professor in 2012. Dr. Kang is the President-Elect of the Metastasis Research Society and Chair of the AACR Tumor Microenvironment Working Group. Dr. Kang‘s outstanding achievements have been recognized by many prestigious awards, including the 2011 Vicek Prize and the 2012 AACR Award for Outstanding Achievements in Cancer Research.

Evi Lianidou

Evi Lianidou

Dr. Evi Lianidou is Professor of Analytical Chemistry and Clinical Chemistry at the Department of Chemistry, University of Athens, Greece. Dr Lianidou has established a Molecular Diagnostics Laboratory focused on Liquid Biopsy at the Department of Chemistry since 1998 (http://en.actc-lab.chem.uoa.gr/). Her lab is specializing in the Analysis of Circulating Tumor Cells (ACTC), and has access to many patient samples through extensive clinical collaborations. Her main research interests are on the development and clinical evaluation of: a) single-plex and multiplex quantitative RT-qPCR assays for the detection and molecular characterization of CTCs, b) multiplex assays for gene expression in CTCs based on the liquid bead array, c) DNA methylation assays in CTCs and ctDNA, d) highly sensitive assays for mutation analysis in CTCs and in ctDNA, and e) evaluation of circulating miRNAs as tumor biomarkers in plasma. Dr. Lianidou has 111 publications (https://www.ncbi.nlm.nih.gov/pubmed/?term=lianidou) and has organized together with Prof K. Pantel four international meetings on liquid biopsy: a) the 7th International Symposium on Minimal Residual Disease in Athens, (http://ismrc2009.chem.uoa.gr) , b) the 1st “Advances in Circulating Tumor Cells: From Basic Research to Clinical Practice” (www.actc2012.org), c) the 2nd ACTC meeting, (October 8th-11th, 2014), in Crete, Greece (www.actc2014.org) and d) the 3rd ACTC meeting, (October 4th-7th, 2017), in Rhodes, Greece (www.actc2017.org). Prof Lianidou is PI in the European TRANSCAN group “CTC-SCAN” and in the EU IMI Network Project “CANCER-ID” (www.cancer-id.eu) and serves on the Editorial Boards of many international journals including Clin Chemistry, Clin. Cancer Res, Breast Cancer Res, Cancer Res, Oncotarget, and many others. Dr. Lianidou is an elected member and Chair of the Committee for Clinical Molecular Biology Curriculum of the International Federation of Clinical Chemistry (IFCC), (http://www.ifcc.org/ifcc-education-division/emd-committees/c-cmbc/) and is coordinating the M.Sc. program of Clinical Chemistry, at the Department of Chemistry, University of Athens (http://en.clinical-chemistry.chem.uoa.gr/).

Y. M. Dennis Lo

Y. M. Dennis Lo

Dennis Lo is the Director of the Li Ka Shing Institute of Health Sciences of The Chinese University of Hong Kong. He received his preclinical medical education from the University of Cambridge and his clinical training and postgraduate research training from the University of Oxford. He discovered the presence of cell-free fetal DNA in maternal plasma in 1997. Since then, he has been pushing forward the frontiers of the biology and diagnostic applications of circulating nucleic acids, in areas covering prenatal testing, oncology, and transplantation. In recognition of his work, Dennis Lo has been elected as a Fellow of the Royal Society and a Foreign Associate of the US National Academy of Sciences.

David Lyden

David Lyden

Dr. David Lyden Early work in Dr. Lyden's laboratory resulted in several fundamental discoveries that involve the role of bone marrow-derived stem and progenitor cells in tumor vasculogenesis and in metastasis. Dr. Lyden and colleagues subsequently identified two bone marrow-derived cell types, endothelial progenitor cells (EPCs) and hematopoietic progenitor cells (HPCs) of myeloid origin that both participate in the formation of new blood vessels in the primary tumor that occurred by vasculogenesis as opposed to angiogenesis. Dr. Lyden's laboratory then went on to show that secreted factors by the primary tumor prime certain tissues for tumor cell engraftment. His laboratory defined the concept of the "pre-metastatic niche". At the pre-metastatic niche, newly recruited bone marrow-derived myeloid progenitor cells collaborate with other cells types residing in the tissue parenchyma. Together, these cells provide a platform of pro-inflammatory molecules, such as S100 family members, growth factors, matrix-degrading enzymes (MMP9) and adhesion molecules (fibronectin and laminin), thereby accelerating assembly of the metastatic lesion. Dr. Lyden's team investigation of tumor-secreted factors that mediate the crosstalk between tumors and cells in the remote metastatic microenvironment has led to his discovery that tumor-secreted microvesicles, known as exosomes, initiate pre-metastatic niche formation by educating stromal cells and bone marrow progenitor cells, thus supporting a pro-metastatic microenvironment. His laboratory has identified key proteins and the presence of nucleic acids in exosomes that support thrombosis generation, vascular leakiness, and pre-metastatic niche formation. Moreover, his group has defined the role of tumor exosomal integrins in organotropic metastasis. Most recently, he and colleagues defined three distinct nanoparticles, Exo-L (90-120nm), Exo-S (60-80nm), and the discovery of a new particle coined exomere (<50nm)  characterized by the adaptation of asymmetric flow field-flow fractionation. 

Dario Marchetti

Dario Marchetti

Dario Marchetti, Ph.D., tumor and molecular biologist, is the Director of the Biomarker Research Program, Professor of the Institute of Academic Medicine at Houston Methodist Research Institute and Visiting Professor of Molecular & Cellular Biology at Baylor College of Medicine. Dr. Marchetti is an international recognized expert and authority in the field of patient-isolated CTCs as clinically useful tools to combat cancer metastasis for improved patient outcome. With keen insights into the biology of brain metastasis, he pioneered models for discoveries of molecular determinants underlying brain metastasis and biomarker properties of brain-homing CTCs (Science Transl. Medicine, 2013), and/or brain-associated CTCs (Nature Communications, 2017).

As a consummate scientist, Dr. Marchetti’s bibliography include 184 publications of which 79 are in peer-reviewed journals in the fields of neuroscience and oncology. He has received numerous awards and secured uninterrupted funding for 27 years by receiving grants from federal, state, institutional and private Agencies. He is a reviewer for the most prominent journals in cancer research and sits on editorial boards of “Cancer Microenvironment, “Tumor Viruses”, “Vascular Cell”, "Clinical & Experimental Pathology", "International Journal of Oncology", “Cancer Letters”, “Journal of Cellular Biochemistry”, “Discovery/Discovery Reports” (a journal from Harvard Medical School) and "Cancer Metastasis Reviews" among others. Dr. Marchetti is Editor-in-Chief of the “Journal of Gene Therapy” and Editor of a Research Topic on CTCs in “Frontiers Oncology”. He also acts as Guest Editor of the special issue on brain metastasis by the International Journal of Molecular Sciences (Basel, Switzerland) and Guest Editor of the special issue “CTCs as Cancer Diagnostics Biomarkers” by Diagnostics (MDPI-Wuhan, China). Further, he served/serves on grant reviewing panels of the National Institutes of Health of USA and Italy, the Department of Defense of the United States, and is frequently invited as grant reviewer and consultant for multiple national and international Agencies and Companies devoted to oncology research.

Dr. Marchetti graduated from the University of Pavia, Italy in 1979. He worked as postdoctoral fellow at the University of Illinois, Chicago (1980-1982), University of Texas Medical Branch – Galveston (Texas) (1984-1986). He then became a research scientist at the University of Texas Health Science Center-Houston (1986-1991), Research Associate and later Instructor at UT MD Anderson Cancer Center (1992-1999), Assistant Professor at UT-Houston (1999-2001), and Associate Professor and later Professor (with tenure) at LSU-Baton Rouge, Louisiana (2002-2007), endowed “Jack. L. Titus” Professor at Baylor College of Medicine (2008-2015; now Visiting Professor) prior to joining the faculty at Methodist Hospital Research Institute.

Joan Massagué

Joan Massagué

Joan Massagué, PhD: Director of Sloan Kettering Institute, Member of the Cancer Biology and Genetics Program. For 23 years Dr. Massagué served as Chairman of the Cancer Biology and Genetics Program and Cell Biology Program at Memorial Sloan Kettering Cancer Center. 1990-2013 he was appointed Investigator of the Howard Hughes Medical Institute and holds an Alfred P. Sloan Chair. He is a member of the National Academy of Sciences and Medicine and many other prestigious organizations. He received numerous awards for his research and recently the Pezcoller Foundation-AACR International Award for Cancer Research and Fellow, AACR Academy. Dr. Massagué is a world leader on investigating the mechanisms by which growth factors, signaling pathways and gene expression programs regulate normal cell proliferation as well as cancer metastasis. The research advances that he has produced are described in over 300 publications in scholarly scientific journals and ranks one of the most highly cited investigators in biomedical sciences.

Thibault Mazard

Thibault Mazard

Dr Thibault Mazard is a medical oncologist specialized in GI cancers. He works at Montpellier Cancer Center (ICM-Val d'Aurelle). He also received a PhD degree in Health and Biology at the University of Montpellier in 2013. He did a post-doctoral fellowship at MD Anderson Cancer Center in Houston working on the developpment of new radiological biomarkers in metastatic colorectal cancer patients treated with bevacizumab. He currently coordinate several clinical trials (COLOSPOT/PANIRINOX/EMUTRAS) evaluating interest of liquid biopsy in the management of metastatic colorectal cancers.

Klaus Pantel

Klaus Pantel

Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg- Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Translational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.) and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and ERC Advanced Investigator Grant 2011. Moreover, Prof Pantel coordinates the European TRANSCAN group “CTC-SCAN”, the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies” and serves on the Editorial Boards of international cancer journals (e.g., Breast Cancer Res., Cancer Res.).

Jean-Yves Pierga

Jean-Yves Pierga

Prof. Jean-Yves Pierga is Professor of Medicine and Medical Oncology at Paris Descartes University since 2005. He is heading the Medical Oncology Department of the Institut Curie, Paris Cancer Center since 2014. His main research interests are breast cancer treatments, early clinical trials and translational research. Pr. Pierga trained as a medical oncologist and obtained a Silver medal from Paris Medical School in 1994. His PhD thesis focused on disseminated tumor cells detection and characterization in breast cancer patients (2003, Paris University XI; Thesis Director: Dr Jean-Paul Thiery). After a post-doctoral fellowship in 2004 at the Royal Marsden London in the Breast Cancer Unit and the Academic Biochemistry Department, Pr. Pierga became head of the Day-clinic at the Institut Curie until 2007. He is currently coheading the Circulating Tumor Biomarkers at the Institut Curie in coordination with Charlotte Proudhon. He has contributed to over 230 peer-reviewed publications. He is member of Société Française de Cancérologie (SFC), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Breast Cancer Group of the EORTC, American Association for Cancer Research (AACR).

Alain Puisieux

Alain Puisieux

Following his Pharmacy internship in Paris (France), Alain Puisieux started a fellowship at the Massachussets General Hospital, Boston (United States, 1989-1991), to investigate the molecular mechanisms of hepatocarcinogenesis. He then joined the Cancer Centre Léon Bérard in Lyon (France), where he created the Molecular Oncology Laboratory in 1997. He was promoted Professor in Biochemistry and Cellular Biology at the Claude Bernard University in 1999. Alain Puisieux headed the U590 Inserm unit “Oncogenesis and tumoral progression” from 2003 to 2010. Currently, he is the Director of the Centre de Recherche en Cancérologie de Lyon (23 teams, 480 staff members). He is a member of the French National Academy of Medicine, of the French National Academy of Pharmacy and a former member of the Institut Universitaire de France. His scientific team focuses its work on the role of EMT-inducing transcription factors in cancer cell plasticity and intra-tumor heterogeneity.


La Région OCCITANIE
Congress date : May 3-5 2018

Organizing committee

Catherine Alix-Panabières
Klaus Pantel

Download Programme

Programme

Important
Dates

  • 15th December 2017
    End of the early registration fees
  • 1st February 2018
    Abstract submission deadline
  • 22nd March 2018
    Notification of abstract acceptance & Travel awards
  • 15th April 2018
    End of the standard registration fees
  • 3rd May 2018
    Opening of the ISMRC 2018

Photo
gallery

Montpellier Go to the gallery